Translarna net product revenue in the quarter was $104,000,000 while Emflaza net product revenue of $57,000,000 Moving to SVT. 1st quarter global revenue of about US400 $1,000,000 was achieved by Roche, earning royalty revenue of $31,000,000 for PTT. Non GAAP R and D expense was $107,000,000 for the Q1 of 2024, excluding $9,000,000 in non cash stock based compensation expense compared to $180,000,000 for the Q1 of 2023, excluding $15,000,000 in non cash stock based compensation expense. The year over year reduction in R and D expenses reflects our strategic portfolio prioritization as the company continues to focus its resources on its differentiated high potential R and D programs. Non GAAP SG and A expense was $64,000,000 for the Q1 of 2024, excluding $9,000,000 in non cash stock based compensation expense compared to $73,000,000 for the Q1 of 2023, excluding $14,000,000 in non cash stock based compensation expense.